The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The Index gained 2 percent in June, outperforming the Dow and the Nasdaq, but underperforming the Nasdaq Biotechnology Index, which gained nearly 9 percent.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
Analysts have released notes to investors refuting the report's claims, calling the short thesis "flawed," and reiterating their ratings for Exact's stock.
The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
The GW Index outperformed the Dow Jones Industrial Average, the Nasdaq Composite, and the Nasdaq Biotech Index.
The GenomeWeb Index rose nearly 5 percent in February, on par with the Dow and slightly outperforming the Nasdaq.
The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.
It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.